The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

James J. Vredenburgh

Department of Medicine

Duke University Medical Center

Durham

NC 27710

USA

[email]@mc.duke.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. 1997 - 2012

References

  1. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Vredenburgh, J.J., Desjardins, A., Kirkpatrick, J.P., Reardon, D.A., Peters, K.B., Herndon, J.E., Marcello, J., Bailey, L., Threatt, S., Sampson, J., Friedman, A., Friedman, H.S. Int. J. Radiat. Oncol. Biol. Phys. (2012) [Pubmed]
  2. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Vredenburgh, J.J., Cloughesy, T., Samant, M., Prados, M., Wen, P.Y., Mikkelsen, T., Schiff, D., Abrey, L.E., Yung, W.K., Paleologos, N., Nicholas, M.K., Jensen, R., Das, A., Friedman, H.S. Oncologist (2010) [Pubmed]
  3. Experience with irinotecan for the treatment of malignant glioma. Vredenburgh, J.J., Desjardins, A., Reardon, D.A., Friedman, H.S. Neuro-oncology (2009) [Pubmed]
  4. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Vredenburgh, J.J., Desjardins, A., Herndon, J.E., Dowell, J.M., Reardon, D.A., Quinn, J.A., Rich, J.N., Sathornsumetee, S., Gururangan, S., Wagner, M., Bigner, D.D., Friedman, A.H., Friedman, H.S. Clin. Cancer Res. (2007) [Pubmed]
  5. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Vredenburgh, J.J., Desjardins, A., Herndon, J.E., Marcello, J., Reardon, D.A., Quinn, J.A., Rich, J.N., Sathornsumetee, S., Gururangan, S., Sampson, J., Wagner, M., Bailey, L., Bigner, D.D., Friedman, A.H., Friedman, H.S. J. Clin. Oncol. (2007) [Pubmed]
  6. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Vredenburgh, J.J., Coniglio, D., Broadwater, G., Jones, R.B., Ross, M., Shpall, E.J., Hussein, A., Rizzieri, D., Marks, L.B., Gilbert, C., Affronti, M.L., Moore, S., McDonald, C., Petros, W.P., Peters, W.P. Biol. Blood Marrow Transplant. (2006) [Pubmed]
  7. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Vredenburgh, J.J., Madan, B., Coniglio, D., Ross, M., Broadwater, G., Niedzwiecki, D., Edwards, J., Marks, L., Vandemark, R., McDonald, C., Affronti, M.L., Peters, W.P. Bone Marrow Transplant. (2006) [Pubmed]
  8. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Vredenburgh, J.J., Silva, O., Broadwater, G., Berry, D., DeSombre, K., Tyer, C., Petros, W.P., Peters, W.P., Bast, R.C. Biol. Blood Marrow Transplant. (1997) [Pubmed]
 
WikiGenes - Universities